Alembic Pharmaceuticals on Tuesday informed that company's joint venture, Aleor Dermaceuticals has received final approval from US Food and Drug Administration (USFDA) for nystatin and triamcinolone acetonide ointment.
Nystatin and triamcinolone Acetonide Ointment is indicated for the treatment of cutaneous candidiasis. It has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) nystatin and triamcinolone acetonide ointment of Taro Pharmaceuticals U.S.A. Inc.According to IQVIA, nystatin and triamcinolone acetonide ointment has an estimated market size of $4 million for twelve months ending December 2021. Alembic said it has received year to date 21 approvals (15 final approvals and 6 tentative approvals) and a cumulative total of 160 ANDA approvals (138 final approvals and 22 tentative approvals) from USFDA.
Shares of Alembic Pharma were trading 0.58% higher at Rs 714.85 on BSE. Meanwhile, the barometer index, the S&P BSE Sensex declined 192.13 points or 0.36% to 52,650.62 amid soaring crude oil prices and ongoing Russia-Ukraine crisis.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. On a consolidated basis, the company reported a 39.7% fall in net profit to Rs 176.42 crore on a 3.2% fall in net sales to Rs 1,271.7 crore in Q3 FY22 over Q3 FY21.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU